A real-world study to assess utilization and clinical outcomes of Daratumumab plus Lenalidomide and Dexamethasone compared to Daratumumab plus Pomalidomide and Dexamethasone in Lenalidomide-exposed or refractory Multiple Myeloma patients at Mayo Clinic
Latest Information Update: 08 Jan 2021
Price :
$35 *
At a glance
- Drugs Bortezomib (Primary) ; Daratumumab (Primary) ; Lenalidomide (Primary) ; Pomalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 08 Jan 2021 New trial record
- 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology